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Results: 60% of patients reported non presence of fatigue 
before the start of RT Fatigue intensity as assessed with the 
VAS increased gradually during radiotherapy, 14 days after 
the end of radiotherapy, the fatigue intensity was still higher 
than before treatment, but 3 months later, fatigue was lower 
than at the pre-treatment level. Fatigue measured with the 
FAQ did not increase significantly during treatment, but the 
subscores on physical and cognitive fatigue were elevated 
during treatment weeks 4 and 5. IL-1b, IL-6, and TNF-a, and 
hemoglobin levels did not change during therapy. Peripheral 
blood cell levels declined significantly during therapy and 
were still low 3 months after treatment. Until treatment 
week 5, lymphocytes were reduced to almost 50% of their 
initial values. Patients that introduce fatigue had 
significantly lower serum levels of cortisol than the 
nonfatigued patients as well as differences in two 
lymphocyte populations, at 3-6 and 12 months after the end 
of radiotherapy 
 
Conclusion: This study has shown that significant fatigue is 
common in patients receiving breast irradiation and is 
precipitated during radiotherapy in some patients but not 
other. In the patients that show an increase of the fatigue 
during adjuvant RT, fatigue returned to pre-treatment levels 
3 months after treatment. In our study, no evidence was 
found that anxiety, depression, serum levels of IL1-b, IL6, 
TNF-a and hemoglobin levels were correlate with treatment 
induced fatigue. The results of our observation suggest the 
existence of a mechanism among activation of the immune 
system and alteration in cortisol and lymphocyte subsets. 
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Purpose or Objective: There has been recent move within 
the U.K. to contour the nodal CTV for patients receiving 
adjuvant radiotherapy for breast cancer. Axillary 
radiotherapy (ART) following a positive sentinel lymph node 
biopsy is becoming more common for certain groups of 
patients. Organs at risk (OAR) should be delineated and 
considered during the planning process. Body mass index 
(BMI) has been shown to impact upon spinal cord and brachial 
plexus doses in irradiation of the supraclavicular fossa. The 
impact upon the OAR in the axilla has not yet been well 
documented.  
 
Material and Methods: Patients undergoing ART between 
01/04/15–01/10/15 were identified. Non - contrast 
radiotherapy planning CT scans were taken. External beam 
radiotherapy was planned with extended tangents using a 
field in field approach with an additional low weighted 
anterior oblique field if deemed appropriate for adequate 
dose coverage. Dose delivered was 40.05 Gy in 15 
fractions.BMI was calculated by: weight(kg)/height (m)2. 
CTV’s were contoured in accordance with the RTOG 
contouring atlas.OAR including ipsilateral lung, humeral head 
and brachial plexus were delineated. 
 
Results: Fifteen patients were identified. Six patients had a 
BMI between 20–25, 3 between 25–30, 5 between 30–40 and 1 
BMI>40. Mean ipsilateral lung V12 was 10.44% (range 2.3%–
14.33%). Mean V12 did not vary with BMI (BMI 20–25;mean 
V12=9.33%, BMI 25–30; mean V12=8.52%, BMI 30–40;mean 
V12=9.51%, BMI>40 mean V12=6.38%, p=0.55 Chi-Squared). 
The mean humeral head maximum dose was 35.2 Gy (range 
1.2–41.5 Gy). Mean humeral head maximum dose did not vary 
with BMI (BMI 20–25; mean=34.2Gy, BMI 25–30;mean=27.8Gy, 
BMI 30–40; mean=40.3Gy, BMI>40; mean=38.2Gy,p=0.49 t-
test). The ipsilateral brachial plexus D2 mean was15.6Gy 
(range 1.2–37.4 Gy). Mean ipsilateral brachial plexus D2 dose 
did not vary with BMI(p=0.21 t-test). 
 
Conclusion: BMI did not significantly impact upon OAR dosage 
although this series is limited by a small sample size. 
Ipsilateral lung and brachial plexus were comfortably within 
departmental tolerance. A planning risk volume of 10 mm 
around the humeral head has now been adopted within the 
department. It is recognised that intravenous contrast 
provides better quality images for delineating OAR in 
particular for the brachial plexus. However, this impacts 
upon resources in terms of radiographer scanning time. 
Adequate time needs to be allocated in consultant and 
physics teams job plans to enable high quality delineation 
and subsequent radiotherapy plans to be produced.  
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Purpose or Objective: Hypothyroidism is the most commonly 
reported long-term toxicity following radiotherapy to 
structures near to the thyroid gland. Emami suggested the 
thyroid gland tolerance as 45Gy (TD 5/5) although a much 
wider range of 10–80 Gy has been reported in the literature. 
When irradiating the supraclavicular fossa (SCF) in adjuvant 
radiotherapy for breast cancer, it is inevitable that the 
thyroid gland will receive a high dose of radiation due to its 
proximity to the target volume. Recently there has been a 
move to CT based delineation of the CTV and organs at risk 
(OAR) in patients requiring nodal radiotherapy for breast 
cancer compared with the previous bony land mark/field 
based techniques. Dose received by the thyroid gland and 
subsequent late toxicity has not yet been well studied in 
breast cancer. 
 
Material and Methods: Patients undergoing external beam 
radiotherapy to the breast or chest wall plus SCF between 
01/04/15–01/10/15 were identified. Radiotherapy planning 
contrast enhanced CT scans were taken. External beam 
radiotherapy was planned with tangents using a field in field 
approach with a matched direct anterior field. A low 
weighted posterior field was added if deemed appropriate for 
adequate dose coverage. Angle corrections were used as 
appropriate. A dose of 40.05 Gy in 15 fractions prescribed at 
depth was employed. CTV’s were contoured in accordance 
with the RTOG contouring atlas.The thyroid gland was 
prospectively delineated and D5% was recorded. 
 
Results: Seventeen patients undergoing adjuvant SCF 
radiotherapy were identified. T stage was as follows: T1:2 
patients,T2:9 patients,T3:4 patients, T4a:1 patient,T4d:1 
patient. N stage; N1:1 patient, N2:14 patients, N3:2 patients. 
Fourteen were hormone receptor positive, 3 hormone 
negative. Twelve were HER2 negative, 5 HER2 positive. Mean 
D5% thyroid was 37.9Gy (range 7–42.7 Gy). Excluding one 
patient with a previous hemi-thyroidectomy, the mean D5% 
thyroid was 39.8 Gy (range 16–42.7 Gy). An abnormality 
requiring referral to a surgeon for was discovered in one 
patient. 
 
Conclusion: Our departmental tolerance for the thyroid 
gland was set as 40Gy (for 2.67Gy per fraction). It is hard to 
achieve this without compromise of the CTV. The effect 
modern chemotherapy/targeted agents may have on this 
prior to receiving radiotherapy is inknown. Baseline TSH 
recording is desirable. Long-term follow up to detect clinical 
or biochemical thyroid dysfunction is needed to inform 
practice but would present challenges with capacity in busy 
oncology departments. 
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Purpose or Objective: The aim of the survey – to compare 
the results of different regimen of whole-breast irradiation 
(accelerated hypofractionated and standard radiation 
treatment) following breast-conserving surgery for breast 
cancer I-IIA stages. 
 
Material and Methods: From 2000 till 2005 203 patients aged 
R54 years received whole-breast irradiation following breast-
conserving surgery (lumpectomy + axillary and internal 
lymphatic dissection). The most commonly seen invasive 
ductal carcinoma (55%), the rare - invasive lobular carcinoma 
(27%), invasive ductal cancer with extensive in situ 
component (3%) and special forms (15%). Metastasis in 
ipsilateral axillary lymph nodes fixed in 17,4% cases. All 
patients received whole-breast irradiation over a five-day 
period with different regimens RT: first group - accelerated 
hypofractionated (AHRT: 3 Gy per fraction over 2,5 weeks, 
total dose of 39 Gy, N=112) and second group - standard 
radiotherapy (SRT: 2Gy per fraction over 5 weeks, total dose 
of 50 Gy, N=91). We used three dimensional CT-based 
treatment planning, two traditional tangential fields 6-18 MV, 
changing the gantry angle, collimator angle, blocks to result 
in coverage of the breast while excluding the heart from the 
treatment fields and minimized dose to the lung. A LQM to 
predict rate of tumor control, late normal tissue effects and 
cosmetic outcome was used in our research. For tumor 
control the value α/β was 4 Gy, acute toxicity – 10 Gy, side 
effects - 3,1 Gy, cosmetic outcome - 3,6 Gy (for AHRT EQD2 
53,0/44,4/46.7/46,0). We calculate (LQM) following formula 
for AHRT:  
 
 
Tumor: k=0,7, Tk=21. 
 
Results: Local recurrence at 5y/10y: 1/3 (1 group) vs 0/1 (2 
group) (p>0.05). Overall survival 5y/10y: 99,1%/95,0% (1 
group) vs. 97,8%/85,0% (2 group), (p<0.05).. Only 8% of the 
patients of the 1 group developed grade 2 erythema and 
14,3% of the patients of the 2 group (p<0,048). No 
complications at heart, сomplications at the lungs (only 1 
degree) 5y/10y: 7(7,7%)/7(7,7%) vs. 6 (5,4%)/6(5,4). The 
other results are presented in Table 1.  
Table 1 (5 and 10 year outcome). 
 
 
 
Conclusion: AHRT decrease adverse effects, increase five 
and ten-year event free survival and cosmetic results vs. SRT. 
We had confirmed our calculations with clinical results. AHRT 
had been proved to be a successful parameters combination 
of a dose for fraction, durations of an irradiation and the 
common dose. Prominent feature of this regimen is increase 
of the tumor control in comparison with SRT, thus early and 
late reactions are essentially decreased 
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Purpose or Objective: To assess the magnitude of inter-
observer contouring uncertainties on CT- and MRI-based boost 
volume contouring in breast cancer patients without clips in 
lumpectomy cavity. 
 
Material and Methods: CT and MRI data-sets of 12 
consecutive patients, treated with surgery (no clips in 
lumpectomy cavity) and postoperative irradiation were 
included. Five experienced radiation oncologists 
independently contoured the boost clinical target volume 
(CTVb) on CT. Three weeks later contouring was repeated on 
MRI. Finally, expert consensus (EC) contours were created on 
both modalities by combining the opinions of all 5 experts. 
Contour Analysis software Tool 1 (CAT 1) was used for global 
volumetric computations and assessment of local contouring 
variation for each case and contouring approach. Inter-
observer volumetric conformity index (VCI) was calculated 
for all pairs of observer’s delineations and the EC contour. In 
topographic analysis, absolute inter-delineation distances 
(IDDs) between observers’ and EC delineations were 
measured in contouring plane (Figure). Paired sample t-test 
was used to for statistical analysis of differences between 
contouring approaches. 
 
Results: None of the observed differences in results were 
statistically significant (p>0.05). Mean CTVb size was 154 +/- 
26 cm3, and 152 +/- 16 cm3, for CT and MRI, respectively. 
Mean relative standard deviation (rSD) revealed higher spread 
of volumes for CT (18 %) when compared with MRI (11 %). 
Mean ratio between the smallest and largest volume was 
comparable (CT: 0.7 +/- 0.1; MRI: 0.8 +/- 0.1). Mean VCI was 
non-significantly higher for MRI (0.81 +/- 0.04) than CT (0.76 
+/- 0.07). MRI-based mean VCI was superior to CT-based 
approach in 10 (83 %) cases. In one case, mean VCI was 
identical (0.88 +/- 0.1), and in one case CT-based VCI (0.81 
+/- 0.04) was slightly superior to MRI (0.8 +/- 0.05). Analysis 
of mean IDD values revealed non-significantly superior results 
for MRI when compared to CT (3 +/- 0.5 mm vs. 4 +/- 1.5 
mm) (Figure). Mean rSD for IDDs was lower on MRI than CT 
contouring (49 % vs. 61 %). In contouring plane, predilection 
regions of variation were in the direction of breast 
parenchyma, while agreement was highest at the breast-
chest wall and breast-air interface (Figure).  
 
 
 
Figure. Example of coordinate system (left) and distance 
maps (right) or topographic assessment of variation.  
 
Conclusion: Although statistically insignificant, superiority of 
MRI over CT for accurate boost delineation in patients 
without clips in lumpectomy cavity may be clinically 
important. We recommend using information from both 
modalities, pre-treatment imaging and clinical information to 
arrive at best results. 
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Purpose or Objective: Our institute started a clinical study 
on radical C-ion RT for patients with low risk T1N0M0 invasive 
